Probiotic Prescription Status of Pediatric Patients with Otitis Media Receiving Oral Amoxicillin or Amoxicillin/Clavulanate from April 2016 to March 2017 Using a Japanese Health Insurance Claims Database

Imai, Shungo; Momo, Kenji; Kashiwagi, Hitoshi; Miyai, Takayuki; Sugawara, Mitsuru; Takekuma, Yoh

Probiotic Prescription Status of Pediatric Patients with Otitis Media Receiving Oral Amoxicillin or Amoxicillin/Clavulanate from April 2016 to March 2017 Using a Japanese Health Insurance Claims Database

Imai, Shungo; Momo, Kenji; Kashiwagi, Hitoshi et al.

Biological & pharmaceutical bulletin, 2021, 44(3), 448-452

Permalink : https://hdl.handle.net/2115/81367

このアイテムのアクセス数:467件（2026-10-12 00:24 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.1248/bpb.b20-00214			25

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/81367
タイトル	Probiotic Prescription Status of Pediatric Patients with Otitis Media Receiving Oral Amoxicillin or Amoxicillin/Clavulanate from April 2016 to March 2017 Using a Japanese Health Insurance Claims Database
著者	Imai, Shungo ; Momo, Kenji ; Kashiwagi, Hitoshi ; Miyai, Takayuki ; Sugawara, Mitsuru ; Takekuma, Yoh
著者名 Imai, Shungo
著者名 Momo, Kenji
著者名 Kashiwagi, Hitoshi
著者名 Miyai, Takayuki
著者名 Sugawara, Mitsuru
e-Rad_Researcher 00396293 著者名 Takekuma, Yoh
言語	英語
キーワード	antibiotic-associated diarrhea
	probiotics
	insurance claim
	oral antibiotics
	pediatric patient
発行日	2021-03
出版者	The Pharmaceutical Society of Japan （日本薬学会）
収録物名	Biological & pharmaceutical bulletin
巻(号)	44(3)
ページ	448-452
抄録	Antibiotic-associated diarrhea (AAD) is a typical side effect of antibiotic treatment, especially in children. Amoxicillin (AMPC) and amoxicillin/clavulanate (AMPC/CVA) are associated with high risk of AAD; however, these antibiotics are important in the pediatric field. Recent research suggests that probiotics prevent pediatric AAD, including that caused by AMPC and AMPC/CVA. Indeed, guidelines for acute otitis media in children recommend the concomitant use of probiotics. However, the prescription status of probiotics for pediatric patients with otitis media receiving oral AMPC and AMPC/CVA remains unknown. We therefore conducted a survey to clarify the current status of these prescriptions and, in particular, to identify specific populations with a low proportion of probiotic prescriptions. Pediatric patients (<15 years of age) newly prescribed oral AMPC or AMPC/CVA for otitis media between April 2016 and March 2017 were identified from a Japanese health insurance claims database. Eligible patients were divided into the AMPC (1303 patients) and AMPC/CVA (424 patients) groups, in which 659 (50.6%) and 293 (69.1%) patients were prescribed probiotics, respectively. Of the patients receiving probiotic prescriptions in the AMPC and AMPC/CVA groups, 632 (95.9%) and 286 (97.6%) patients received antibiotic-resistant probiotic prescriptions, respectively. When classified by the prescribing clinical department and patient age, the proportions of probiotic prescriptions in Internal Medicine and Pediatrics departments were lower than those in the Otorhinolaryngology department regardless of age. These results indicate the probability of insufficient probiotic prescriptions for pediatric patients with otitis media. Solving this issue may lead to the provision of safer antimicrobial therapy.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
PISSN	0918-6158
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1248/bpb.b20-00214